Our Story

 

Our mission: To improve human health and quality of life by transforming the way therapeutics and materials are discovered.

With steadfast investment in R&D, we continue to develop and refine our scientific platform. Our platform is deployed by users worldwide to enable the discovery of novel therapeutics and materials more rapidly, at a lower cost, and we believe with a higher likelihood of success. It is also the foundation of our internal drug discovery initiatives to develop first-in-class therapies.

Schrödinger through the years

EXPLORE

1990
Co-founders Richard Friesner and Bill Goddard launch Schrödinger
1992
First software sale, to Brookhaven National Laboratory
1995
First investment from David E. Shaw
2001
Release Glide, which offers high-throughput virtual screening of millions of compounds
2003
Release Prime, a fully integrated protein structure prediction program
2009
Release WaterMap, the first rigorous method for computing protein-bound water locations and energetics
Co-found Nimbus Therapeutics with Atlas Venture
2010
First investment from Bill Gates
Launch collaboration with Agios, which will lead to two FDA-approved oncology drugs
2012
Launch Materials Science division
2014
Release FEP+, the first benchmark method for accurately predicting binding affinity differences among molecules with a common core
Release LiveDesign, a next-generation platform for collaborative drug design
2016
Launch collaboration with Sanofi to support drug discovery with computational resources
Gilead acquires Nimbus ACC program for $1.2B
2017
Launch research collaboration with Takeda to accelerate drug discovery
2018
Launch Cryo-EM Initiative to join global research centers in leveraging cryo-electron microscopy
Launch collaboration with SPARC to accelerate neurodegeneration drug development
2019
Co-found Faxian Therapeutics drug development company with WuXi AppTec
Close $110 million funding round
2020
Initial Public Offering
Back To Top